MCP-1 contributes to arteriovenous fistula failure

Journal of the American Society of Nephrology

Volumn 22, Issue 1, 2011, Pages 43-48

  Juncos, Julio P ^a   Grande, Joseph P ^a   Kang, Lu ^a   Ackerman, Allan W ^a   Croatt, Anthony J ^a   Katusic, Zvonimir S ^a   Nath, Karl A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL INJURY; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; KIDNEY ARTERIOVENOUS FISTULA; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR PATENCY; VEIN WALL;

EID: 78651405679     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010040373     Document Type: Article

References (30)

1. Agarwal A, Segal MS: Intimal exuberance: Veins in jeopardy. Am J Pathol 162: 1759-1761, 2003
2. Allon M: Current management of vascular access. Clin J Am Soc Nephrol 2: 786-800, 2007
3. Durante W, Lin CC: Homing in on arteriovenous fistula survival. Kidney Int 74: 9-11, 2008
4. Roy-Chaudhury P, Spergel LM, Besarab A, Asif A, Ravani P: Biology of arteriovenous fistula failure. J Nephrol 20: 150-163, 2007
5. Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, Meyer K, Beasley D: Vascular access for hemodialysis. Kidney Int 55: 2078-2090, 1999
6. Daly C, Rollins BJ: Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: Therapeutic opportunities and controversies. Microcirculation 10: 247-257, 2003
7. Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-621, 2006
8. Deshmane SL, Kremlev S, Amini S, Sawaya BE: Monocyte chemoattractant protein-1 (MCP-1): An overview. J Interferon Cytokine Res 29: 313-326, 2009
9. Schober A: Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 28: 1950-1959, 2008
10. Tesch GH: MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 294: F697-F701, 2008
11. Juncos JP, Tracz MJ, Croatt AJ, Grande JP, Ackerman AW, Katusic ZS, Nath KA: Genetic deficiency of heme oxygenase-1 impairs functionality and form of an arteriovenous fistula in the mouse. Kidney Int 74: 47-51, 2008
12. Kokubo T, Ishikawa N, Uchida H, Chasnoff SE, Xie X, Mathew S, Hruska KA, Choi ET: CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas. J Am Soc Nephrol 20: 1236-1245, 2009
13. Croatt AJ, Grande JP, Hernandez MC, Ackerman AW, Katusic ZS, Nath KA: Characterization of a model of an arteriovenous fistula in the rat: The effect of L-NAME. Am J Pathol 176: 2530-2541, 2010
14. Stinghen AE, Goncalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, Pecoits-Filho R: Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract 111: c117-c126, 2009
15. De Marchi S, Cecchin E, Falleti E, Giacomello R, Stel G, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E: Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 8: 1147-1156, 1997
16. De Marchi S, Falleti E, Giacomello R, Stel G, Cecchin E, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E: Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 7: 1169-1177, 1996 (Pubitemid 27468269)
17. Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, Memmos D: Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: Association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 17: 435-441, 2002 (Pubitemid 34211140)
18. Buraczynska M, Bednarek-Skublewska A, Buraczynska K, Ksiazek A: Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients. Cytokine 44: 361-365, 2008
19. Nath KA, Kanakiriya SK, Grande JP, Croatt AJ, Katusic ZS: Increased venous proinflammatory gene expression and intimal hyperplasia in an aorto-caval fistula model in the rat. Am J Pathol 162: 2079-2090, 2003
20. Gruden G, Setti G, Hayward A, Sugden D, Duggan S, Burt D, Buckingham RE, Gnudi L, Viberti G: Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: Inhibition by rosiglitazone. J Am Soc Nephrol 16: 688-696, 2005
21. Schepers A, Eefting D, Bonta PI, Grimbergen JM, de Vries MR, van Weel V, de Vries CJ, Egashira K, van Bockel JH, Quax PH: Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 26: 2063-2069, 2006
22. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C: Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: Involvement of IL-10. Blood 107: 4240-42543, 2006
23. Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, Liehn EA, van Santbrink PJ, Nelson PJ, Biessen EA, Mertens PR, Weber C: Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 116: 1812-1820, 2007
24. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Mach F, Weber C: Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27: 373-379, 2007
25. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F: A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 28: 1090-1096, 2008
26. Hla T, Oo ML: Ramping up RANTES in the acute response to arterial injury. J Clin Invest 120: 90-92, 2010
27. Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, Luttropp K, Nordfors L, Lindholm B, Brandenburg V, Schalling M, Stenvinkel P, Boeschoten EW, Krediet RT, Navis G, Dekker FW: CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 20: 1641-1649, 2009
28. Watson D, Zheng G, Wu H, Wang YM, Wang Y, Harris DC, Alexander SI: CCL2 DNA vaccine to treat renal disease. Int J Biochem Cell Biol 41: 729-732, 2009
29. Shin N, Baribaud F, Wang K, Yang G, Wynn R, Covington MB, Feldman P, Gallagher KB, Leffet LM, Lo YY, Wang A, Xue CB, Newton RC, Scherle PA: Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2. Biochem Biophys Res Commun 387: 251-255, 2009
30. Wolff RA, Tomas JJ, Hullett DA, Stark VE, van Rooijen N, Hoch JR: Macrophage depletion reduces monocyte chemotactic protein-1 and transforming growth factor-beta1 in healing rat vein grafts. J Vasc Surg 39: 878-888, 2004